Results of application of chemical destruction in complex treatment of focal hepatic pathology

Dronov, O.I.; Kovalska, I.; Коzachuk, E. S.; Bakunets, P.P.

doi:10.26779/2522-1396.2019.05.12

Cited by 1 publication

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Sugiura, 1983 as cited in Shiina, et al,2018). Також використовують 50% оцтову кислоту, гідроксид натрію та 10% розчин кальцію хлориду (Dronov, Kovalska, Коzachuk, et al, 2019;Yu, H., & Burke, 2014;).…”

Section: матеріали і методиunclassified

“…На основі експериментальних та клінічних досліджень, автори встановили безпечність та ефективність застосування 10% розчину кальцію хлориду для ПХА злоякісних новоутворень печінки. У основі цитодеструктивної дії даного хімічного агенту лежить здатність викликати виражений некроз біологічних тканин, шляхом дегідратації клітин-мішеней та тромбозу судин мікроциркуляторного русла (Dronov, Kovalska, Коzachuk, et al, 2019;.…”

Section: матеріали і методиunclassified

See 1 more Smart Citation

Застосування Перкутанної Хімічної Абляції В Лікуванні Пацієнтів З Гепатоцелюлярною Карциномою

Левченко

Kozachuk

Земсков

2020

USMYJ

View full text Add to dashboard Cite

In the world, the incidence of HCC constantly increases each year. In the period from 1990 to 2015, the rate of newly diagnosed cases of HCC increased by 75%. In Ukraine in 2018, only 18.0% of primary patients were gotten special treatment: 4.9% only by surgery, 2.0% by combined and complex treatment. Unsatisfactory results of special treatment coverage are associated with the peculiarities of the etiopathogenesis of HCC, asymptomatic course, and improper screening system of patients at risk, which leads to difficulty in diagnosis of HCC in the early stages. The choice of HCC treatment tactics, associated with viral hepatitis and liver cirrhosis, remains a difficult clinical challenge. The radical treatment at an early stage HCC is a cornerstone for improving overall survival. Percutaneous ablation (PA) was developed for inoperable patients with HCC in the early stages and liver cirrhosis. There are radiofrequency ablation, chemical ablation, cryoablation, microwave ablation, etc. The main indications for the local ablation application are very early and early-stage (according to BCLC - stage 0 and A), compensated or subcompensated liver function in cirrhosis (Child-Pugh class A and B), ECOG 0-1, the diameter of the tumor lesion up to 5.0 cm (most optimally up to 3.0 cm), focal nodal lesion, solitary or multiple lesion. Percutaneous ablation is used as a bridge therapy to local tumor control in patients who undergo the Milan and the UCSFC criteria and are on the waiting list for transplantation. These methods have also shown their effectiveness as neoadjuvant "downstaging" therapy in patients who are not candidates for liver transplantation and/or with initially unresectable lesions. For many decades, percutaneous chemical ablation has been the “gold” standard for minimally invasive treatment of HCC. This method is easy to perform, does not require special equipment, is well tolerated by patients, safe, and cost-effective. The main chemical agents are ethanol and acetic acid. The percutaneous chemical ablation procedure involves intratumoral administration of a chemical agent a real-time under the control of imaging (ultrasound or CT). Chemical ablation is a second-line method and is used only in cases where there are contraindications to radiofrequency ablation. This method is not accompanied by severe specific complications and mortality. The effectiveness of its clinical application directly depends on the size of the tumor. The optimal size of the tumor is not more than 3.0 cm. Intratumoral administration of ethano promotes necrosis of 90% -100% of HCC with a diameter of ≤ 2.0 cm and 70% for tumors with 2.0 - 3.0 cm

show abstract

Section: матеріали і методиunclassified